Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Scopolamine in the Treatment of Major Depression
IRCT201201181556N31Phase 3Completed
- Sponsor
- Tehran University of Medical Sciences
- Start
- Nov 2011
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3 trial of scopolamine in major depressive disorder (MDD), sponsored by Tehran University of Medical Sciences. Started Nov 2011; status: completed.
02
Drugs
scopolamine
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on IRCT201201181556N31.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT201201181556N31.